Pharma

Sanofi's and Regeneron's Dupixent wins new stage of EU regulatory approval

  • January 27, 2023 07:24 AM CET | Reuters
 Sanofi's and Regeneron's Dupixent wins new stage of EU regulatory approval

287 (Adds details in paragraphs 3 and 4) PARIS, Jan 27 (Reuters) - Healthcare companies Sanofi and Regeneron said on Friday the European Union's medicines regulator had given a new stage of approval for

Read More...

Gensight Biologics End-Dec Cash Position At EUR 10.6 Mln

Gensight Biologics End-Dec Cash Position At EUR 10.6 Mln

  • January 26, 2023 07:38 AM CET | Reuters

Jan 26 (Reuters) - Gensight Biologics SA: * GENSIGHT BIOLOGICS REPORTS CASH POSITION AS OF DECEMBER 31, 2022, FY 2022 REVENUES AND PROVIDES BUSINESS UPDATE * GENSIGHT BIOLOGICS' CASH AND CASH

Read More...
Lysogene Announces Conversion Of Safeguard Proceedings Into Reorganization Proceedings

Lysogene Announces Conversion Of Safeguard Proceedings Into Reorganization Proceedings

  • January 25, 2023 08:08 AM CET | Reuters

Jan 25 (Reuters) - Lysogene SA: * LYSOGENE: CONVERSION OF THE SAFEGUARD PROCEEDINGS INTO REORGANIZATION PROCEEDINGS * THIS REQUEST WAS EXAMINED AND APPROVED BY COMMERCIAL COURT OF NANTERRE AT HEARING

Read More...
Poxel Receives Orphan Drug Designation From EC For PXL770, PXL065

Poxel Receives Orphan Drug Designation From EC For PXL770, PXL065

  • January 25, 2023 07:32 AM CET | Reuters

Jan 25 (Reuters) - Poxel SA: * POXEL RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR PXL770 AND PXL065 FOR TREATMENT OF ADRENOLEUKODYSTROPHY * POXEL RECEIVES ORPHAN DRUG DESIGNATION

Read More...
Innate Pharma: Hart-Scott-Rodino Clearance Regarding Expansion Of Collaboration With Sanofi On NK Cell Engagers

Innate Pharma: Hart-Scott-Rodino Clearance Regarding Expansion Of Collaboration With Sanofi On NK Cell Engagers

  • January 25, 2023 07:02 AM CET | Reuters

Jan 25 (Reuters) - Innate Pharma SA: * ANNOUNCES HART-SCOTT-RODINO CLEARANCE REGARDING EXPANSION OF ITS COLLABORATION WITH SANOFI ON NK CELL ENGAGERS * ANNOUNCED TODAY EXPIRATION OF WAITING PERIOD

Read More...
Medincell Announces Initiation Of Phase 3 Study For Injectable Antipsychotic

Medincell Announces Initiation Of Phase 3 Study For Injectable Antipsychotic

  • January 24, 2023 06:15 PM CET | Reuters

Jan 24 (Reuters) - Medincell SA: * INITIATION OF THE PHASE 3 STUDY FOR THE SECOND LONG-ACTING INJECTABLE ANTIPSYCHOTIC USING MEDINCELL’S TECHNOLOGY (PROGRAM MDC-TJK) * PHASE 3 STUDY CONDUCTED IN U.S.

Read More...
Neovacs: Commits To Project To Transform Pharnext's Legal Structure

Neovacs: Commits To Project To Transform Pharnext's Legal Structure

  • January 24, 2023 08:35 AM CET | Reuters

Jan 24 (Reuters) - Neovacs SA: * NEOVACS SA - MADE COMMITMENT ALONGSIDE PHARNEXT S.A. AS PART OF THE PROJECT TO TRANSFORM LATTER INTO SOCIETE EN COMMANDITE PAR ACTIONS (S.C.A.). Source text:

Read More...
Advicenne FY Sales Up At €3.7 Million

Advicenne FY Sales Up At €3.7 Million

  • January 24, 2023 07:03 AM CET | Reuters

Jan 24 (Reuters) - Advicenne SA: * ADVICENNE REPORTS 2022 SALES UP 13% TO €3.7 MILLION * SIGNIFICANT GROWTH ACCELERATION IN H2 2022 * ANNOUNCES TODAY 2022 SALES OF €3.7 MILLION, UP 13% COMPARED TO THE

Read More...
Hyloris: Commercial Partnership For Maxigesic® ® IV In 9 European Countries

Hyloris: Commercial Partnership For Maxigesic® ® IV In 9 European Countries

  • January 24, 2023 07:03 AM CET | Reuters

Jan 24 (Reuters) - Hyloris Pharmaceuticals SA: * HYLORIS ANNOUNCES COMMERCIAL PARTNERSHIP FOR MAXIGESIC® IV IN 9 EUROPEAN COUNTRIES * EXCLUSIVE LICENSING AND DISTRIBUTION AGREEMENT SIGNED WITH SALUS

Read More...
Eurobio Scientific FY Turnover Down At 152.5 Million Euros

Eurobio Scientific FY Turnover Down At 152.5 Million Euros

  • January 23, 2023 05:50 PM CET | Reuters

Jan 23 (Reuters) - Eurobio Scientific SA: * 2022 TURNOVER OF EUR 152.5M * 15% CORE BUSINESS GROWTH AT EUR 93M * AT END OF 2022, EUROBIO SCIENTIFIC'S CASH POSITION WAS OVER EUR 85 MILLION, FOR A NET

Read More...
Cellectis Amends $20 Mln Convertible Note Under Collaboration Agreement With Cytovia Therapeutics

Cellectis Amends $20 Mln Convertible Note Under Collaboration Agreement With Cytovia Therapeutics

  • January 20, 2023 10:32 PM CET | Reuters

Jan 20 (Reuters) - Cellectis Sa: * CELLECTIS AMENDS $20 MILLION CONVERTIBLE NOTE UNDER COLLABORATION AGREEMENT WITH ITS PARTNER CYTOVIA THERAPEUTICS * AMENDED AND RESTATED NOTE INCREASED APPLICABLE

Read More...

Frequently Asked Questions

3232